Beam Therapeutics Inc (BEAM)

Beam Therapeutics Shares Climb After Positive BEAM-302 Trial UpdateMarch 25, 2026 10:04 AM
IH Market News
Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) gained about 8% on Wednesday after the company released updated results from its ongoing Phase 1/2 clinical study of BEAM-302, a treatment being developed for alpha-1 antitrypsin deficiency (AATD).According to the company, patients receiving a 60 mg dose of BEAM-302 achieved a mean steady-state total AAT level of 16.1 µM. All treated patients maintained levels consistently above the protective threshold of 11 µM, with follow-up data extending up to 12 months. Corrected M-AAT represented 94% of total AAT, while levels of the mutant Z-AAT protein were reduced by 84% following treatment with the 60 mg dose.BEAM-302 is a liver-targeted lipid nanoparticle therapy designed to correct the genetic mutation responsible for the severe form of AATD using base editing technology. The treatment is currently being studied in a Phase 1/2 open-label trial assessing its safety, tolerability, pharmacokinetics, pharmacodynamics, and overall effectiveness.As of the February 10 data cutoff, a total of 29 patients had received BEAM-302, with follow-up periods reaching up to 18 months. Among 26 patients treated with a single dose, the therapy demonstrated a favorable safety profile at doses up to 75 mg. Reported adverse events were generally mild to moderate, with no serious adverse events or dose-limiting toxicities recorded by the cutoff date.Based on the observed safety and efficacy across the single-dose cohorts, the company selected 60 mg as the optimal biological dose. Beam said it plans to launch a global pivotal cohort in the second half of 2026 to support a potential accelerated regulatory approval.Researchers also observed a dynamic increase in AAT expression in one patient in the 60 mg cohort during a respiratory infection. In that case, total AAT levels rose from a steady-state level of 15.9 µM to 29.5 µM, while the AAT composition remained stable at 95% M-AAT.In Part B of the trial, which includes patients with AATD-related liver disease, single doses of 30 mg and 60 mg of BEAM-302 produced efficacy results consistent with those seen in Part A participants who did not have liver disease.Beam Therapeutics stock price

Original: Beam Therapeutics Shares Climb After Positive BEAM-302 Trial Update

BEAM, new 52 week low

Up to $170 million in total purchases by Ark, stock still dropping like a rock. Now below $20.

As if 3/24, the ARK funds own about $43 million of stock, most bought at prices ranging from 24-33.

If Kathy is Buying I'm shorting it! Good ole Inverse Kathy Woods signal

$BEAM

ARK funds have been big buyers lately.

BEAM under $30

BEAM range bound

BEAM under $50

BEAM shares were again a purchase by Cathie Wood
I am not certain the shares have another significant bounce left

I bought 3153 shares yesterday at $21.

I figured if Cathie Wood added 22,220 shares to the ARK portfolio, it was good enough for me to add to mine.

On Monday, Cathie Wood-led Ark Invest made a notable move...
October 2, 2023

Ark Invest purchased 92,853 shares of SomaLogic Inc (NASDAQ:SLGC), a notable player in the biotechnology sector through ARKG.
The firm also acquired 45,1942 shares of Recursion Pharmaceuticals (NASDAQ:RXRX), marking a significant addition to its holdings through ARKG.
22,220 shares of Beam Therapeutics Inc (NASDAQ:BEAM) were added to Ark's portfolio, emphasizing its focus on innovative biotech firms through.

BEAM Focuses on Developing Gene Drug for Growth
9:06 am ET October 10, 2023

Beam Therapeutics’ BEAM proprietary base-editing technology potentially enables the development of a differentiated class of precision genetic medicines that target a single base in the genome without making a double-stranded break in the DNA, thereby minimizing errors.

The company is pursuing two primary approaches depending on tissue type in vivo programs that use intravenously administered CRISPR as the therapy and ex vivo programs that use CRISPR to create the therapy using engineered human cells.

BEAM is evaluating its leading ex-vivo genome-editing candidate, BEAM-101, in the phase I/II BEACON study for sickle cell disease (SCD). It has successfully consented enough patients projected to both fill the sentinel cohort and initiate the expansion cohort of the early-stage study.

Apart from BEAM-101, the company is evaluating BEAM-201, a therapy designed to create allogeneic CD7, targeting CAR-T cells resistant to fratricide and immunosuppression. BEAM-201 is actively enrolling patients at multiple clinical sites, in a phase I/II study for treating patients with T-cell leukemia and T-cell lymphoblastic lymphoma, a severe disease affecting children and adults, and potentially other CD7+ malignancies.

The company also has two pre-clinical candidates —BEAM-301 and BEAM-302 — in its portfolio for genetic diseases.

BEAM has initiated IND-enabling studies for both candidates and plans to submit a regulatory application to begin clinical studies in the first half of 2024.

While the company is yet to have an approved marketable product in its pipeline, its collaboration deals help access capabilities and resources to support the ongoing therapeutic programs.

BEAM collaborated with Pfizer PFE in 2021, focusing on using its gene-editing technology to create treatments for rare genetic diseases that affect the liver, muscles and the central nervous system. It is conducting the research work for three specific gene-editing programs. If these programs prove effective in clinical studies, Pfizer can choose to help develop and sell them globally, with both companies sharing the costs and profits.

Nothing in the paper on how they plan to overcome NK cell rejection.

Even more preclinical data https://www.biorxiv.org/content/10.1101/2023.08.03.551705v1

How about treating someone?!

https://twitter.com/crisprtalk/status/1680190176255942656

Nice one month move off the double bottom…

https://www.the-scientist.com/news-opinion/first-person-dosed-in-novel-gene-editing-clinical-trial-70223

"Verve Therapeutics announced today (July 12) that it has dosed the first participant in a clinical trial assessing the safety and tolerability of the gene editing platform VERVE-101, which uses a precise kind of gene editing called base editing. By changing a single DNA nucleotide, VERVE-101 can inactivate a gene expressed in the liver that is linked to high cholesterol in people with a hereditary and potentially life-threatening subtype of cardiovascular disease called heterozygous familial hypercholesterolemia (HeFH).

“The dosing of the first human with such an investigational base editing medicine represents a significant achievement by our team and for the field of gene editing,” Sekar Kathiresan, the cofounder and chief executive officer of Verve Therapeutics, says in a press release. “Preclinical data suggest that VERVE-101 has the potential to offer people with HeFH a game-changing treatment option, transforming the traditional chronic care model to a single-course, life-long treatment solution.”

Prior to the trial, HeFH and other conditions that manifest in high levels of LDL cholesterol (so-called bad cholesterol) were treated using dietary and lifestyle changes combined with cholesterol-lowering drugs that have to be administered one or two times a month. This regimen can be difficult for patients to adhere to, Gary Balady, the director of preventive cardiology at Boston Medical Center, tells The Boston Globe, and only about 20 percent of patients are able to achieve their goals. Balady, who was not involved in the trial, adds that “having a one-time treatment has the potential to save lots of lives.”

VERVE-101 edits a single nucleotide within the genetic code for PCSK9, a gene expressed in the liver. PCSK9 encodes an enzyme that regulates the amount of cholesterol in the plasma by binding to LDL receptors on liver cell membranes. Certain heritable forms of HeFH are caused by mutations in the genes; by substituting an adenine base for a guanine, the base editing tool induces a new, intentional mutation that renders the defective gene inactive, lowering the level of LDL in a person’s body and, consequently, reducing the risk of developing cardiovascular diseases such as HeFH.

In preclinical studies using nonhuman primates, VERVE-101 lowered levels of LDL cholesterol by roughly 70 percent after two weeks, and the levels remained low for at least two years, Kathiresan tells the Globe.

“This seems like a bigger effect than I would have predicted,” Sarah de Ferranti, the chief of ambulatory cardiology at Boston Children’s Hospital, who was not involved in the work, tells the Globe. She adds that even if the treatment were only half as effective in humans, “I still think that would be a huge game changer.”

The human trial, which received regulatory approval in May, includes roughly 40 adults with HeFH who will receive one of three dosing regimens. The first person to receive a dose lives in New Zealand, where the trial was approved, but Verve Therapeutics also plans to seek permission from regulators this year to expand it into the UK and the US, Biopharma Dive reports. Preliminary trial results are expected in 2023.

ABOVE:
© ISTOCK.COM, VCHAL

Verve Therapeutics announced today (July 12) that it has dosed the first participant in a clinical trial assessing the safety and tolerability of the gene editing platform VERVE-101, which uses a precise kind of gene editing called base editing. By changing a single DNA nucleotide, VERVE-101 can inactivate a gene expressed in the liver that is linked to high cholesterol in people with a hereditary and potentially life-threatening subtype of cardiovascular disease called heterozygous familial hypercholesterolemia (HeFH).

“The dosing of the first human with such an investigational base editing medicine represents a significant achievement by our team and for the field of gene editing,” Sekar Kathiresan, the cofounder and chief executive officer of Verve Therapeutics, says in a press release. “Preclinical data suggest that VERVE-101 has the potential to offer people with HeFH a game-changing treatment option, transforming the traditional chronic care model to a single-course, life-long treatment solution.”

Prior to the trial, HeFH and other conditions that manifest in high levels of LDL cholesterol (so-called bad cholesterol) were treated using dietary and lifestyle changes combined with cholesterol-lowering drugs that have to be administered one or two times a month. This regimen can be difficult for patients to adhere to, Gary Balady, the director of preventive cardiology at Boston Medical Center, tells The Boston Globe, and only about 20 percent of patients are able to achieve their goals. Balady, who was not involved in the trial, adds that “having a one-time treatment has the potential to save lots of lives.”

VERVE-101 edits a single nucleotide within the genetic code for PCSK9, a gene expressed in the liver. PCSK9 encodes an enzyme that regulates the amount of cholesterol in the plasma by binding to LDL receptors on liver cell membranes. Certain heritable forms of HeFH are caused by mutations in the genes; by substituting an adenine base for a guanine, the base editing tool induces a new, intentional mutation that renders the defective gene inactive, lowering the level of LDL in a person’s body and, consequently, reducing the risk of developing cardiovascular diseases such as HeFH.

In preclinical studies using nonhuman primates, VERVE-101 lowered levels of LDL cholesterol by roughly 70 percent after two weeks, and the levels remained low for at least two years, Kathiresan tells the Globe.

“This seems like a bigger effect than I would have predicted,” Sarah de Ferranti, the chief of ambulatory cardiology at Boston Children’s Hospital, who was not involved in the work, tells the Globe. She adds that even if the treatment were only half as effective in humans, “I still think that would be a huge game changer.”

The human trial, which received regulatory approval in May, includes roughly 40 adults with HeFH who will receive one of three dosing regimens. The first person to receive a dose lives in New Zealand, where the trial was approved, but Verve Therapeutics also plans to seek permission from regulators this year to expand it into the UK and the US, Biopharma Dive reports. Preliminary trial results are expected in 2023.

Base editing technology has only recently made its way to human trials, and VERVE-101 is not the first. This year, researchers at University College London launched a clinical trial to treat leukemia using base editing tools, and the Boston-based biotech company Beam Therapeutics, which licensed some of its technology to Verve Therapeutics, will launch a trial later this year using a base editor to treat people with blood disorders such as sickle cell disease and beta thalassemia, the Globe reports. But these trials involve modifying patients’ cells outside of their body before infusing them back in; Verve Therapeutics joins a short list of companies that have developed treatments meant to edit genes directly in the body.

David Liu, the Broad Institute of MIT and Harvard University researcher who first developed base editing in 2016, tells the Globe that he hopes to see many more platforms in the coming year, noting that “to be able to take control of our genomes, to me, is one of the most human things we can do” to alleviate suffering.

But Jennifer Doudna of the University of California, Berkeley, one of the researchers credited with coinventing CRISPR gene editing in 2012, notes that even base editing—generally thought to be safer than other CRISPR techniques because it manipulates a smaller chunk of the genome—is not without risk, and she doesn’t yet think CRISPR has the precision to correct point mutations. There can be off-target effects, she tells the Globe, meaning that you “end up usually getting more editing than you might want.”

See “Base Editors Cause Off-Target Mutations in RNA”
The repercussions of these effects are not yet known, but John Evans, the chief executive of Beam Therapeutics, tells the Globe that these off-target edits are somewhat predictable, and potentially something that can be avoided. “You can kind of engineer around it,” he says.

c

Biotechs have been hot recently. No worries about tax loss selling this year.

LOL

Blue sky breakout!


$BEAM

Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee


How about them apples!


$BEAM

Beam me up Scotty lol lmao

Beasting out!

$BEAM

Revenue 24k........ 0.00% revenue per... Never seen an Operating Margin of -1,269,908.4% negative 1 million & a quarter percent

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -1,269,908.40%

Management Effectiveness
Return on Assets (ttm) -37.50%
Return on Equity (ttm) -106.96%

Income Statement
Revenue (ttm) 24k
Revenue Per Share (ttm) 0.00
Quarterly Revenue Growth (yoy) 0.00%
Gross Profit (ttm) 24k
EBITDA -299.74M
Net Income Avi to Common (ttm) -365.69M
Diluted EPS (ttm) -6.76

Balance Sheet
Total Cash (mrq) 503.48M
Total Cash Per Share (mrq) 8.23
Total Debt (mrq) 136.59M
Total Debt/Equity (mrq) 32.33
Current Ratio (mrq) 5.04
Book Value Per Share (mrq) 6.91

Cash Flow Statement
Operating Cash Flow (ttm) -106.93M
Levered Free Cash Flow (ttm) -126.99M

Kaboomage


$BEAM

Reloaded $69.00-$71.00 will ride it to new highs.




$BEAM

Starting buying at $15.00 Will add if it dips into the low 80.00s again.


I have no problem adding the dips and buying quality stocks for the long term.


$BEAM

What a beast!

$BEAM

I am "beaming" with BEAM

(sorry, I could not resist)

Short Shrift for Short-Sighted Short Sellers

Desmond Wheatley CEO Beam Global

Dear friends, shareholders, employees and supporters,

The United States has the most efficient capital markets in the world. It’s part of what makes this nation great. During the last hundred years or so, this efficient use of capital has enabled the greatest period of innovation in human history. The stock market provides companies access to the capital they need to succeed and investors the opportunity to share in that success. An efficiently functioning stock market is critical to a healthy economy.

There are many ways in which investors can participate in the stock market. One, which is receiving a great deal of attention at the moment, is short selling. As a public company CEO and an issuer, I have mixed feelings about short selling. I recognize that it can be a useful contributor to a healthy and efficient stock market because it can help in identifying and correcting overvalued securities. An honest and informed short seller that analyzes a company’s business plan, operations, finances, leadership and prospects, and finds that company to be overvalued, can profit by coming to that conclusion before the rest of the market inevitably identifies the same weaknesses. I’m in favor of that. One should not pity the target of that kind of short selling, particularly if the overvaluation is driven by unrealistic or even dishonest projections on the part of the issuer.

But what if the issuer is not dishonest and the projections are reasonable? What if certain short sellers create a narrative just to support their short position? They know that if they can be convincing enough, in an already opaque and complicated world, that the seeds of doubt they sow can lead to selling and price depreciation. They know that they can profit from the losses of the shareholders who believe, correctly, in the issuer. That’s not efficient, that’s dishonest. That kind of behavior does not support innovation and entrepreneurialism. It destroys the opportunities created by the inventiveness and hard work of the entrepreneur, and it destroys the value of the position of the honest investor. It undermines the essential ingredient in the investor’s arsenal – reliable information.

I get a lot of advice in my capacity as CEO of Beam Global. One of the most common is that I should not take negative comments about the company personally. Well, I do take them personally. Like everything else to do with the company, I take them very personally indeed. I love this company and I am very proud of the team, the products, our customers and our shareholders. It’s insulting to our hard-working team, our discerning (often repeat) customers and our loyal supporters and shareholders to suggest that we are anything other than what we say we are.

Almost all public comments about Beam are resoundingly positive. We have regular corporate and government customer endorsements in our press releases (I’m told that that is unusual by our Public Relations company). I personally spend a great deal of time on the phone, in video meetings or face to face with customers, shareholders, vendors and other interested parties. I am always willing to listen to constructive criticism during those interactions and the overwhelming majority of feedback I get is positive – very positive. We have never had a product returned or any customer that regrets driving on sunshine.

But I know that from time to time, particularly when our share price has increased in value, there will be those who will attempt to profit from sowing the seeds of doubt about our products, our plan, our team and our leadership.

Most businesses are fairly complex. Beam is one of the simpler and easier to understand but even so, it’s not difficult to selectively identify historical data points, magnify insignificancies and cast half-truths, opinions and falsehoods as supporting facts to a negative narrative. That has happened and it will happen again. Where there’s profit there’s motive and where there’s motive there’s often action.

Fortunately for Beam, there is a lot of good and honest research available for the discerning investor. Professional, hard-working Wall Street analysts who have spent months researching our company and the industries in which we operate, have released detailed and well researched reports. Reports for which Beam paid nothing. Reports over which Beam had no influence or input other than to answer the questions of the analysts and to open our factory, products and business practices to their scrutiny. Their conclusions are unanimously positive.

Those who have come to the opposite conclusion have never contacted us, never seen our operations, never tested our products and never shown the slightest inclination to do so. They have created the negative narrative but without the hard work required to know the truth. I will leave it up to the investment community to conclude what their motivations might be.

Beam Global is in the best position in our history. The (global) political, consumer, market and environmental conditions are firmly in our favor. Our ability to execute, be financially responsible and grow have been proven in fact over the last many years. If you read or hear something about Beam which makes you doubt us, take a look at the published respected analysts’ reports about us or all the very positive comments made by our customers. If you don’t get the answers you are looking for there, then contact me. My direct line and direct email are at the bottom of this letter. Remember, I have a company to run and I owe it to our customers, employees and shareholders not to spend all my time responding to nefarious commentary, but I’ll say it again, contact me. Ask me your questions, no matter how tough you think them. If disclosure rules allow, I’ll answer them in the only way I know how – honestly and with pride in what we are doing.

We have fantastic opportunities ahead of us. I could not be more enthusiastic about what I see coming in 2021 and beyond for Beam. I believe that concentrating on the nexus of clean energy and transportation will continue to place us in one of the most exciting transitions in history. We will vigorously pursue profits doing something we can all be very proud of. Thank you for being involved and let us all ensure that facts and truth guide us, and not allow those who know nothing, and care even less, about our fundamentals to slow us down, even for a second.

Desmond Wheatley
President, CEO and Chairman of the Board

Added a 1000 shares today.


$BEAM

Beam investors i was in early here in the teens. Next ARKG gene editing stock that is going to run hard is EVGN

$EVGN
$BEAM

BEAM Sold half like i said at $100.00 riding the rest for free now. Parlayed more into HGEN.

BEAM
https://newsrts.com/2020/12/29/why-beam-therapeutics-inc-beam-stock-could-see-much-higher-prices-ahead/


HGEN
https://www.globenewswire.com/news-release/2019/07/02/1877284/0/en/Humanigen-Secures-Exclusive-Worldwide-License-to-Gene-Editing-Technology-from-Mayo-Clinic-to-Improve-CAR-T.html


BEAM 5.5 billion market cap
HGEN 800 million market cap phase 3 CV-19 deep pipeline partnered with Gilead & KITE & MAYO & NIH BARDA

$BEAM

will start selling part of my holdings at $100.00 love this company!

500%+ since summer!

$BEAM

my $15.00's looking good!

always early.


https://gfycat.com/infantilemammothboar-goodwillhunty-caseyaffleck-drama


$BEAM

News: $BEAM Here's Why Shares of Editas Medicine and Beam Therapeutics Are Soaring Today

Shares of Editas Medicine (NASDAQ: EDIT) and Beam Therapeutics (NASDAQ: BEAM) rose as much as 23% and 29%, respectively, today after the pair were rumored to be considering a merger. Although investors shouldn't invest based on speculation, a merger would make sense on multiple fronts. ...

Got this from BEAM - Here's Why Shares of Editas Medicine and Beam Therapeutics Are Soaring Today

Cached weekly for the record...

This is making news all over. Just heard it on the FM as well.

RIP ticker $BEAM me up Scotty

Wow, there goes another nice vehicle.

wish I got those 700 shares @ 70.13 when news hit



BEAM

BEAM buy out $83.50= http://ih.advfn.com/p.php?pid=nmona&article=60639534&symbol=BEAM

Very nice.. Watch close I guess.. Some stocks breaking higher and many look to turn lower. Strange times.

October 2011 ;)

Go Jimmy, Go!!!

$$$$$$$$ $BEAM me up Scotty!!! $$$$$$$$$$

Kinda toppy on the weekly though..








PennyStockTweets ~ http://www.pennystocktweets.com/stocks/profile/BEAM


OTC Markets Company Info ~ http://www.otcmarkets.com/stock/BEAM/company-info
OTC Markets Charts ~ http://www.otcmarkets.com/stock/BEAM/chart
OTC Markets Quote ~ http://www.otcmarkets.com/stock/BEAM/quote
OTC Markets News ~ http://www.otcmarkets.com/stock/BEAM/news
OTC Markets Financials ~ http://www.otcmarkets.com/stock/BEAM/financials
OTC Markets Short Sales ~ http://www.otcmarkets.com/stock/BEAM/short-sales
OTC Markets Insider Disclosure ~ http://www.otcmarkets.com/stock/BEAM/insider-transactions
OTC Markets Research Reports ~ http://www.otcmarkets.com/stock/BEAM/research


Google Finance Summary ~ http://www.google.com/finance?q=BEAM
Google Finance News ~ http://www.google.com/finance/company_news?q=BEAM
Google Finance Option chain ~ http://www.google.com/finance/option_chain?q=BEAM
Google Finance Financials ~ http://www.google.com/finance?q=BEAM&fstype=ii#
Google Finance Historical prices Daily ~ http://www.google.com/finance/historical?q=BEAM
Google Finance Historical prices Weekly ~ http://www.google.com/finance/historical?q=BEAM&histperiod=weekly#


Y! < Company >
Y! Profile ~ http://finance.yahoo.com/q/pr?s=BEAM+Profile
Y! Key Stat's ~ http://finance.yahoo.com/q/ks?s=BEAM+Key+Statistics
Y! Headlines ~ http://finance.yahoo.com/q/h?s=BEAM+Headlines
Y! Summary ~ http://finance.yahoo.com/q?s=BEAM
Y! Historical Prices ~ http://finance.yahoo.com/q/hp?s=BEAM+Historical+Prices
Y! Order Book ~ http://finance.yahoo.com/q/ecn?s=BEAM+Order+Book
Y! Message Boards ~ http://messages.finance.yahoo.com/mb/BEAM
Y! Market Pulse ~ http://finance.yahoo.com/marketpulse/BEAM
Y! Technical Analysis ~ http://finance.yahoo.com/q/ta?s=BEAM+Basic+Tech.+Analysis
Y! < Analyst Coverage >
Y! Analyst Opinion ~ http://finance.yahoo.com/q/ao?s=BEAM+Analyst+Opinion
Y! Analyst Estimates ~ http://finance.yahoo.com/q/ae?s=BEAM+Analyst+Estimates
Y! Research Reports ~ http://finance.yahoo.com/q/rr?s=BEAM+Research+Reports
Y! Star Analysts ~ http://finance.yahoo.com/q/sa?s=BEAM+Star+Analysts
Y! < Ownership >
Y! Major Holders ~ http://finance.yahoo.com/q/mh?s=BEAM+Major+Holders
Y! Insider Transactions ~ http://finance.yahoo.com/q/it?s=BEAM+Insider+Transactions
Y! Insider Roster ~ http://finance.yahoo.com/q/ir?s=BEAM+Insider+Roster
Y! < Financials >
Y! Income Statement ~ http://finance.yahoo.com/q/is?s=BEAM+Income+Statement&annual
Y! Balance Sheet ~ http://finance.yahoo.com/q/bs?s=BEAM+Balance+Sheet&annual
Y! Cash Flow ~ http://finance.yahoo.com/q/cf?s=BEAM+Cash+Flow&annual


FINVIZ ~ http://finviz.com/quote.ashx?t=BEAM&ty=c&ta=0&p=d


Investorshub Trades ~ http://ih.advfn.com/p.php?pid=trades&symbol=BEAM
Investorshub Board Search ~ http://investorshub.advfn.com/boards/getboards.aspx?searchstr=BEAM
Investorshub PostStream ~ http://investorshub.advfn.com/boards/poststream.aspx?ticker=BEAM
Investorshub Messages ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=BEAM
Investorshub Videos ~ http://ih.advfn.com/p.php?pid=ihvse&ihvqu=BEAM
Investorshub News ~ http://ih.advfn.com/p.php?pid=news&btn=s_ok&ctl00%24sb3%24tbq1=Get+Quote&as_values_IH=&ctl00%24sb3%24stb1=Search+iHub&symbol=BEAM&s_ok=OK&from_month=3&from_day=15&from_year=2012&order=desc&selsrc%5B%5D=prnca&selsrc%5B%5D=prnus&selsrc%5B%5D=zacks&selsrc%5B%5D=money2&selsrc%5B%5D=djn&selsrc%5B%5D=bw&selsrc%5B%5D=globe&selsrc%5B%5D=edgar&selsrc%5B%5D=mwus&force=1&last_ts=1331855999&p_n=1&p_count=&p_ts=1331794260


CandlestickChart ~ http://www.candlestickchart.com/cgi/chart.cgi?symbol=BEAM&exchange=US


Barchart Quote ~ http://barchart.com/quotes/stocks/BEAM?
Barchart Detailed Quote ~ http://barchart.com/detailedquote/stocks/BEAM
Barchart Options Quotes ~ http://barchart.com/options/stocks/BEAM
Barchart Technical Chart ~ http://barchart.com/charts/stocks/BEAM&style=technical
Barchart Interactive Chart ~ http://barchart.com/charts/stocks/BEAM&style=interactive
Barchart Technical Analysis ~ http://barchart.com/technicals/stocks/BEAM
Barchart Trader's Cheat Sheet ~ http://barchart.com/cheatsheet.php?sym=BEAM
Barchart Barchart Opinion ~ http://barchart.com/opinions/stocks/BEAM
Barchart Snapshot Opinion ~ http://barchart.com/snapopinion/stocks/BEAM
Barchart News Headlines ~ http://barchart.com/news/stocks/BEAM
Barchart Profile ~ http://barchart.com/profile//BEAM
Barchart Key Statistics ~ http://barchart.com/profile.php?sym=BEAM&view=key_statistics


OTC: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=BEAM&MarketTicker=OTC&TYP=S
NASDAQ: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=BEAM&MarketTicker=NASD&TYP=S
NYSE: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=BEAM&MarketTicker=NYSE&Typ=S


Marketwatch Profile ~ http://www.marketwatch.com/investing/stock/BEAM/profile
Marketwatch Analyst Estimates ~ http://www.marketwatch.com/investing/stock/BEAM/analystestimates
Marketwatch Historical Quotes ~ http://www.marketwatch.com/investing/stock/BEAM/historical
Marketwatch Financials ~ http://www.marketwatch.com/investing/stock/BEAM/financials
Marketwatch Overview ~ http://www.marketwatch.com/investing/stock/BEAM
Marketwatch SEC Filings ~ http://www.marketwatch.com/investing/stock/BEAM/secfilings
Marketwatch Picks ~ http://www.marketwatch.com/investing/stock/BEAM/picks
Marketwatch Hulbert ~ http://www.marketwatch.com/investing/stock/BEAM/hulbert
Marketwatch Insider Actions ~ http://www.marketwatch.com/investing/stock/BEAM/insideractions
Marketwatch Options ~ http://www.marketwatch.com/investing/stock/BEAM/options
Marketwatch Charts ~ http://www.marketwatch.com/investing/stock/BEAM/charts
Marketwatch News ~ http://bigcharts.marketwatch.com/news/symbolsearch/symbolnews.asp?news=markadv&symb=BEAM&sid=1795093&framed=False


The Lion ~ http://thelion.com/bin/aio_msg.cgi?cmd=search&msg=&si=1&tw=1&tt=1&rb=1&ih=1&fo=1&iv=1&yf=1&sa=1&fb=1&gg=1&symbol=BEAM


Search NYSE ~ http://www.nyse.com/about/listed/lcddata.html?ticker=BEAM


StockTA ~ http://www.stockta.com/cgi-bin/analysis.pl?symb=BEAM&num1=567&cobrand=&mode=stock


StockHouse ~ http://www.stockhouse.com/financialtools/sn_overview.aspx?qm_symbol=BEAM
StockHouse Delayed LII ~ http://www.stockhouse.com/financialtools/sn_level2.aspx?qm_page=46140&qm_symbol=BEAM


AlphaTrade ~ http://tools.alphatrade.com/index.php?t1=mc_quote_module&t2=mc_quote_module2&t3=historical&template=historical2html&sym=BEAM&client_id=2740&a_width=680&a_height=1000&language=english&showVol=1&chtype=8


Reuters ~ http://www.reuters.com/finance/stocks/companyOfficers?symbol=BEAM.PK&WTmodLOC=C4-Officers-5


StockWatch ~ http://www.stockwatch.com/Quote/Detail.aspx?symbol=BEAM®ion=U


Search NASDAQ ~ http://www.nasdaq.com/symbol/BEAM
NASDAQ Divy History ~ http://www.nasdaq.com/symbol/BEAM/dividend-history
NASDAQ Short Interest ~ http://www.nasdaq.com/symbol/BEAM/short-interest
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/BEAM/institutional-holdings
NASDAQ FlashQuotes ~ http://www.nasdaq.com/aspx/flashquotes.aspx?symbol=BEAM&selected=BEAM
NASDAQ InfoQuotes ~ http://www.nasdaq.com/aspx/infoquotes.aspx?symbol=BEAM&selected=BEAM
NASDAQ After Hours Quote ~ http://www.nasdaq.com/symbol/BEAM/after-hours
NASDAQ Pre-Market Quote ~ http://www.nasdaq.com/symbol/BEAM/premarket
NASDAQ Historical Quote ~ http://www.nasdaq.com/symbol/BEAM/historical
NASDAQ Option Chain ~ http://www.nasdaq.com/symbol/BEAM/option-chain
NASDAQ Company Headlines ~ http://www.nasdaq.com/symbol/BEAM/news-headlines
NASDAQ Press Releases ~ http://www.nasdaq.com/symbol/BEAM/news-headlines
NASDAQ Sentiment ~ http://www.nasdaq.com/symbol/BEAM/sentiment
NASDAQ Analyst Summary ~ http://www.nasdaq.com/symbol/BEAM/analyst-research
NASDAQ Guru Analysis~ http://www.nasdaq.com/symbol/BEAM/guru-analysis
NASDAQ Stock Report ~ http://www.nasdaq.com/symbol/BEAM/stock-report
NASDAQ Competitors ~ http://www.nasdaq.com/symbol/BEAM/competitors
NASDAQ Stock Consultant ~ http://www.nasdaq.com/symbol/BEAM/stock-consultant
NASDAQ Stock Comparison ~ http://www.nasdaq.com/symbol/BEAM/stock-comparison
NASDAQ Call Transcripts ~ http://www.nasdaq.com/symbol/BEAM/call-transcripts
NASDAQ Annual Reports ~ http://www.nasdaq.com/aspx/annualreport.aspx?symbol=BEAM&selected=BEAM
NASDAQ Financials ~ http://www.nasdaq.com/symbol/BEAM/financials
NASDAQ Revenue & Earnings Per Share (EPS) ~ http://www.nasdaq.com/symbol/BEAM/revenue-eps
NASDAQ SEC Filings ~ http://www.nasdaq.com/symbol/BEAM/sec-filings
NASDAQ Ownership Summary ~ http://www.nasdaq.com/symbol/BEAM/ownership-summary
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/BEAM/institutional-holdings
NASDAQ (SEC Form 4) ~
--------- All Trades ~ http://www.nasdaq.com/symbol/BEAM/insider-trades
--------- Buys ~ http://www.nasdaq.com/symbol/BEAM/insider-trades/buys
--------- Sells ~ http://www.nasdaq.com/symbol/BEAM/insider-trades/sells


The Motley Fool ~ http://caps.fool.com/Ticker/BEAM.aspx
The Motley Fool Earnings/Growth ~ http://caps.fool.com/Ticker/BEAM/EarningsGrowthRates.aspx?source=itxsittst0000001
The Motley Fool Ratios ~ http://caps.fool.com/Ticker/BEAM/Ratios.aspx?source=itxsittst0000001
The Motley Fool Stats ~ http://caps.fool.com/Ticker/BEAM/Stats.aspx?source=icasittab0000006
The Motley Fool Historical ~ http://caps.fool.com/Ticker/BEAM/Historical.aspx?source=icasittab0000004
The Motley Fool Scorecard ~ http://caps.fool.com/Ticker/BEAM/Scorecard.aspx?source=icasittab0000003
The Motley Fool Statements ~ http://caps.fool.com/Ticker/BEAM/Statements.aspx?source=icasittab0000009


MSN Money ~ http://investing.money.msn.com/investments/stock-ratings?symbol=BEAM


YCharts ~ http://ycharts.com/companies/BEAM
YCharts Performance ~ http://ycharts.com/companies/BEAM/performance
YCharts Dashboard ~ http://ycharts.com/companies/BEAM/dashboard


InsideStocks Opinion ~ http://www.insidestocks.com/texpert.asp?sym=BEAM&code=XDAILY
InsideStocks Profile ~ http://www.insidestocks.com/profile.asp?sym=BEAM&code=XDAILY
InsideStocks Quote ~ http://www.insidestocks.com/quote.asp?sym=BEAM&code=XDAILY
InsideStocks Projection ~ http://charts3.barchart.com/procal.asp?sym=BEAM


Zacks Quote ~ http://www.zacks.com/stock/quote/BEAM
Zacks Estimates ~ http://www.zacks.com/research/report.php?type=estimates&t=BEAM
Zacks Company Reports ~ http://www.zacks.com/research/report.php?type=report&t=BEAM


Knobias ~ http://knobias.10kwizard.com/files.php?sym=BEAM


StockScores ~ http://www.stockscores.com/quickreport.asp?ticker=BEAM


Trade-Ideas ~ http://www.trade-ideas.com/StockInfo/BEAM/.html


Morningstar ~ http://performance.morningstar.com/stock/performance-return.action?region=USA&t=BEAM&culture=en-US
Morningstar Shareholders ~ http://investors.morningstar.com/ownership/shareholders-overview.html?t=BEAM®ion=USA&culture=en-us
Morningstar Transcripts~ http://www.morningstar.com/earnings/NoTranscript.aspx?t=BEAM®ion=USA
Morningstar Key Ratios ~ http://financials.morningstar.com/ratios/r.html?t=BEAM®ion=USA&culture=en-US
Morningstar Executive Compensation ~ http://insiders.morningstar.com/trading/executive-compensation.action?t=BEAM®ion=USA&culture=en-us
Morningstar Valuation ~ http://financials.morningstar.com/valuation/price-ratio.html?t=BEAM®ion=USA&culture=en-us


CCBN (Thompson Reuters) ~ http://ccbn.aol.com/company.asp?client=aol&ticker=BEAM


TradingMarkets ~ http://pr.tradingmarkets.com/?lid=leftPRbox&sym=BEAM


OTCBB ~ http://www.otcbb.com/asp/SiteSearch.asp?Criteria=BEAM&searcharea=e&image1.x=0&image1.y=0


Insidercow ~ http://www.insidercow.com/history/company.jsp?company=BEAM&B1=Search%21


Forbes News ~ http://search.forbes.com/search/find?tab=searchtabgeneraldark&MT=BEAM
Forbes Press Releases ~ http://search.forbes.com/search/find?&start=1&tab=searchtabgeneraldark&MT=BEAM&pub=businesswire,prnewswire&searchResults=pressRelease&tag=pr&premium=on
Forbes Web ~ http://search.forbes.com/search/web?MT=UNGS&start=1&max=10&searchResults=web&tag=web&sort=null


YouTube Symbol Search ~ http://www.youtube.com/results?search_query=BEAM


Buy-Ins ~ http://www.buyins.net/tools/symbol_stats.php?sym=BEAM


Quotemedia ~ http://www.quotemedia.com/results.php?qm_page=47556&qm_symbol=BEAM


Earnings Whispers ~ http://www.earningswhispers.com/stocks.asp?symbol=BEAM

Bloomberg Snapshot ~ http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=BEAM
Bloomberg People ~ http://investing.businessweek.com/research/stocks/people/people.asp?ticker=BEAM

Financial Times ~ http://markets.ft.com/Research/Markets/Tearsheets/Summary?s=BEAM

Hoovers ~ http://www.hoovers.com/search/company-search-results/100003765-1.html?type=company&term=BEAM

DD Machine ~ http://www.ddmachine.com/default.asp?m=stocktool_frame.asp?symbol=BEAM

SEC Form 4 ~ http://www.secform4.com/insider/showhistory.php?cik=BEAM

OTCBB Pulse ~ http://www.otcbbpulse.com/cgi-bin/pulsequote.cgi?symbol=BEAM

Failures To Deliver ~ http://failurestodeliver.com/default2.aspx enter "BEAM" and click search.

http://www.coordinatedlegal.com/SecretaryOfState.html

http://regsho.finra.org/regsho-Index.html

http://www.shortsqueeze.com/?symbol=BEAM&submit=Short+Quote%99



DTCC (PENSON/TDA) Check - (otc and pinks) - Note ~ I did not check for this chart blast. However, I try and help you to do so with the following links.
IHUB DTCC BOARD SEARCH #1 http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=BEAM
IHUB DTCC BOARD SEARCH #2: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=14482&srchyr=2011&SearchStr=BEAM
Check those searches for recent BEAM mentions. If BEAM is showing up on older posts and not on new posts found in link below, The DTCC issues may have been addressed and fixed. Always call the broker if your security turns up on any DTCC/PENSON list.
http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=Complete+list
For a complete list see the pinned threads at the top here ---> http://tinyurl.com/TWO-OLD-FARTS


To ask me about BEAM click here ---> http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2012&SearchStr=BEAM

MACDlinks MACDScan

Pucker™ Vodka Expands Boldly-Flavored Vodka Portfolio with the Launch of Two New Expressions
Date : 02/21/2012 @ 8:00AM
Source : PR Newswire
Stock : Beam Inc. Common Stock (BEAM)
Quote : 55.11 -0.91 (-1.62%) @ 2:44PM



Pucker™ Vodka Expands Boldly-Flavored Vodka Portfolio with the Launch of Two New Expressions
PrintAlert
Beam Inc. Common Stock (NYSE:BEAM)
Intraday Stock Chart
Today : Tuesday 21 February 2012
Pucker™ Vodka Expands Boldly-Flavored Vodka Portfolio with the Launch of Two New Expressions Pucker™ Lemonade Lust Vodka and Pucker™ Raspberry Rave Vodka Join the Fast-Growing Flavored Vodka Line
PR Newswire

DEERFIELD, Ill., Feb. 21, 2012





DEERFIELD, Ill., Feb. 21, 2012 /PRNewswire/ -- Pucker™ Vodka continues to surprise flavored vodka fans with its distinct and unexpected flavors. Now, one year after bursting on the scene, Pucker Vodka is introducing two bold, intense flavors – Pucker™ Lemonade Lust Vodka and Pucker™ Raspberry Rave Vodka – to the family.

All six Pucker Vodka flavors are perfect for those looking to break up with their boring vodka and to match up with an exciting and new intensely flavored vodka.


"Last year, we launched Pucker Vodka to help flavored vodka drinkers express their 'live out loud' personalities, and they certainly responded well to our original flavors," said Kim Washington, Senior Director, Vodkas for Beam Inc. "This year, we chose to expand our line to include two of the most popular flavors – lemonade and raspberry – to help liven up old, boring, vodka cocktails."

Pucker Lemonade Lust Vodka provides bright bursts of crisp lemon flavor and a hint of lime, while Pucker Raspberry Rave Vodka offers an intense raspberry flavor and a touch of floral notes. Both new products are four-times distilled, 70-proof, and packed with intense flavor. Each of the new flavors provides a taste that is balanced and confident enough to enjoy with a simple mixer, served straight-up or in a playful cocktail creation.

To demonstrate its stand-out and unique new flavors, Pucker Vodka recommends these cocktails:

Lusty Lemon 1 1/2 parts Pucker™ Lemonade Lust Vodka 2 parts Fresh Lemon Sour 4 parts Iced Tea Lemon Wedge Combine ingredients and serve over ice in a tall highball glass. Garnish with a lemon wedge.

Raspberry Breeze 1 1/2 parts Pucker™ Raspberry Rave Vodka 2 parts Grapefruit Juice 2 parts Cranberry Juice Lemon Wedge Combine ingredients in order and serve over ice in a tall highball glass. Garnish with a lemon wedge.

Lemonade Lust and Raspberry Rave are available nationwide in February at a suggested retail price of $15.99 for a 750ml bottle. For more information, please go to www.puckervodka.com or www.facebook.com/puckervodka.

About Pucker™ Vodka

Pucker™ Vodka is made from natural flavors, combined with a vodka that's distilled four times to deliver full flavor that can be enjoyed straight or mixed in any cocktail. Pucker Vodka creates a unique sensory vodka experience unlike any other flavored vodka on the market today. Flavors include Sour Apple Sass, Grape Gone Wild, Cherry Tease, Citrus Squeeze, Lemonade Lust and Raspberry Rave.

About Beam Inc.

As one of the world's leading premium spirits companies, Beam is Crafting the Spirits that Stir the World. Consumers from all corners of the globe call for the company's brands, including Jim Beam Bourbon, Maker's Mark Bourbon, Sauza Tequila, Canadian Club Whisky, Courvoisier Cognac, Teacher's Scotch Whisky, Kilbeggan Irish Whiskey, Laphroaig Scotch Whisky, Cruzan Rum, Hornitos Tequila, Knob Creek Bourbon, EFFEN Vodka, Pucker Flavored Vodka, Larios Gin, Whisky DYC, DeKuyper Cordials, and Skinnygirl Cocktails. The Beam portfolio includes 10 of the world's top 100 premium spirits brands and some of the industry's fastest growing innovations. Beam is focused on delivering superior performance with its unique combination of scale with agility and a strategy of Creating Famous Brands, Building Winning Markets and Fueling Our Growth. Beam and its 3,200 passionate associates worldwide generated 2011 sales of $2.8 billion on volume of 34 million 9-liter cases.


Headquartered in Deerfield, Illinois, Beam is traded on the New York Stock Exchange under the ticker symbol BEAM and is included in the S&P 500 Index and the MSCI World Index. For more information on Beam, its brands, and its commitment to social responsibility, please visit www.beamglobal.com and www.drinksmart.com.

Pucker™ Flavored Vodka, 35% Alc./Vol. 100% Grain Neutral Spirits ©2012 Fielding & Jones Ltd., Clermont, KY; Frankfort, KY; Cincinnati, OH Facebook is a registered trademark of Facebook, Inc.

~ $BEAM ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $BEAM ~ Earnings expected on Friday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=BEAM&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=BEAM&p=W&b=3&g=0&id=p54550695994



~ Barchart: http://barchart.com/quotes/stocks/BEAM?
~ OTC Markets: http://www.otcmarkets.com/stock/BEAM/company-info
~ Google Finance: http://www.google.com/finance?q=BEAM
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=BEAM#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=BEAM+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=BEAM
Finviz: http://finviz.com/quote.ashx?t=BEAM
~ BusyStock: http://busystock.com/i.php?s=BEAM&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=BEAM&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=BEAM
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=BEAM
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=BEAM
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=BEAM
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=BEAM
~ MarketWatch: http://www.marketwatch.com/investing/stock/BEAM/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=BEAM
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=BEAM
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=BEAM&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=BEAM&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=BEAM&size=l&frequency=60&color=g


http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

big mkt analysts...WDKA to soon have coverage of its own

WDKA is Davey vs. Goliath here

here comes WDKA

BEAM HOD 47.51 - 10% gain

ex-dividend date today?